Clinical Trial Update: Safety and Efficacy of BGS649 in Obese, Hypogonadotropic Hypogonadal Men [Phase 2]

View source ↗

Summary

Phase 2 trial investigating safety and efficacy of BGS649 in obese men with hypogonadotropic hypogonadism was terminated with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obese Hypogonadotropic Hypogonadism

Drugs mentioned

• BGS649

Snippet

Sponsor: Mereo BioPharma | Conditions: Obese Hypogonadotropic Hypogonadism | Phase 2 | Status: TERMINATED | Results posted: 2020-10-08